Skip to content

MYIG

Mydecine Innovations Group Inc

Access


ISIN

CA62849F2008

Bid

8.00

Mid

8.50

Ask

9.00

Key Information

Price Change
0.00%
Year High
10.00
Year Low
8.50
Last Trade
10 Nov 23
Market Cap
£4.47M
Bid
8.00
Mid Price
8.50
Ask
9.00
Instrument Type
Ordinary Shares
MIFID Status
MTF
Tradable Securities
52.57M
Sector
Healthcare

Prices in GBX except for Market Cap in GBP

About Mydecine Innovations Group Inc

The Company is an emerging biotech and life sciences company dedicated to developing and commercialising innovative solutions for treating mental health problems and enhancing wellbeing. The Company’s medical and scientific advisory board is building out an R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. The Company currently has several clinical initiatives involving its lead drug candidate MYCO-001 (a form of purified psilocybin) with multiple research institutions, globally. Further, the Company has designed severallibraries of novel molecules believed to have enhanced safety and efficacy profiles. The Company is currently working with its pre-clinical team at the University of Alberta to work these molecules through the Investigational New Drug enabling stage with the intent to put them into human clinical studies expected to commence in 2024. The Company has a comprehensive intellectual property strategy covering novel molecules, drug formulations, delivery mechanisms, and methods of production. The Company believes this covers all described drug development activities in our named pipeline and clinical trials. The Company has filed these applications both in the United States and through the Patent Cooperation Treaty (PCT) for protection in all jurisdictions in which the Company does business.

Mydecine Innovations Group IncAccess

Latest Trades

DateVolumePrice (GBX)Value (GBP)

10 Nov 23

10:15

1,0009.9099.00

08 Nov 23

11:07

10,0009.90990.00

07 Nov 23

15:01

10,00010.001,000.00

03 Nov 23

13:54

10,0009.90990.00

03 Nov 23

11:39

10,2479.70993.96
View all trades

Latest Announcements & Notices

DateTitle

31 Oct 23

07:00

Mydecine Innovations Group Inc - MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT, ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENTS

26 Oct 23

07:00

Mydecine Innovations Group Inc - Q4 2023 Business Update

13 Oct 23

18:06

Mydecine Innovations Group Inc - Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK

11 Oct 23

01:00

Market Notice - Correction on Admission to Trading Announcement
View all announcementsView all notices

Address

Registered Address

Suite 810-789, West Pender Street, Vancouver, NULL, V6C 1H2, Canada

Email

jbartch@mydecineinc.com

Phone

+1 (720) 277-9879

Contacts

Corporate Adviser

Novum Securities, 2nd Floor, 7-10 Chandos Street, London, W1G 9DQ, United Kingdom

Registrar

Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds, LS1 4DL, United Kingdom
Loading...

Company

  • About
  • News
  • Investor Relations
  • Contact
  • Careers

© Aquis Exchange 2023. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal